Programme

THEME - PAIN IN OSTEOARTHRITIS

Tuesday 22 April

Morning Session

0800 Registration

0830 - 0835 Welcome by Chairmen/Organisers

Session 1: OSTEOARTHRITIS - Aetiology and Clinical Manifestations
Chair: Prof Kim Rainsford / Dr Michael Powanda

0835 - 0900
Osteoarthritis: symptoms and signs (1)*
Prof Walter Kean, McMaster University, Hamilton, Canada

0900 - 0930
Cartilage cell biology of osteoarthritis (2)
Prof Linda Sandell, Washington University School of Medicine, St Louis, MO, USA

0930 - 0955
Regulation of bone lysis in inflammatory diseases (3)
Dr David Haynes, University of Adelaide, Australia

0955 - 1020
Vascular mechanisms in osteoarthritis and relevance to treatment agents (4)
Dr Philip Cheras, University of Queensland, Brisbane, Australia

1020 - 1045
Molecular regulation of chronic inflammation (5)
Prof Jack Gauldie, McMaster University, Hamilton, Canada

 

1045 - 1110 Coffee/Tea

 

1110 - 1135
Experimental pain models - mechanisms of pain( 6)
Dr Steve Gauldie, University of Edinburgh, Edinburgh, UK

1135 - 1200
Health status assessment in research and clinical practice environments in OA (7)
Prof Nick Bellamy, University of Queensland, Australia

1200 - 1225
The impatient patient: a personal view of osteoarthritis (8)
Dr Michael Powanda, M/P Biomedical Consultants LLC, Mill Valley, CA, USA

 

1225 - 1330 Lunch

 

Afternoon Session

Session 2: OSTEOARTHRITIS - Therapeutics
Chair: Prof Laurie Prescott / Prof Walter Kean

1330 - 1355
Therapy of pain in OA - no drugs? (9)
Prof Paul Dieppe, Medical Research Council & University of Bristol, Bristol, UK

1355 - 1420
Global treatments for OA (10)
Prof George Ehrlich, University of Pennsylvania, Philadelphia, PA, USA

1420 - 1445
NSAIDs and opioids in the treatment of OA (11)
Dr Géza Bálint, National Institute of Rheumatology & Physiotherapy

1445 - 1510
Meloxicam, a COX-2 selective NSAID: what's a nice drug like you doing in a class like this? (12)
Dr Albert Agro, Boehringer-Ingelheim Canada, Burlington, Ontario, Canada

1510 - 1535
Dexibuprofen: pharmacology, therapeutic uses and safety (13)
Dr Stefan Kähler, Gebro Pharma GmbH, Fieberbrunn, Austria

 

1535 - 1600 Coffee/Tea

 

1600 - 1625
Place of OTC analgesics and NSAIDs in self-medication of OA (14)
Prof Nicholas Moore, University of Bordeaux II, Bordeaux, France

1625 - 1650
Assessment of the safety of COX-2 selective drugs (15)
Prof Richard Hunt, McMaster University, Hamilton, Ontario, Canada

1650 - 1730
HOT Topic: NSAIDs may prevent breast cancer
Prof Kim Rainsford and others

DEBATE: COX-2 selective drugs, NSAIDs versus analgesics in OA; is some COX-1 inhibition desirable for analgesia?
Chair: Prof Kim Rainsford
All participants

1800 - 1930 Reception

 

---

Wednesday 23 April

Morning Session

0800 Registration

Session 3: OSTEOARTHRITIS - Emerging Developments
Chair: Prof George Nuki / Prof George Ehrlich

0820 - 0845
Current strategies and emerging developments (16)
Prof Frank Wollheim, Lund University Hospital, Lund, Sweden

0845 - 0910
Phase III results of licofelone (ML-3000), an inhibitor of COX-1, COX-2 and 5-LOX, in OA and endoscopic studies (17)
Prof Stefan Laufer, University of Tübingen, Tübingen, Germany

0910 - 0935
Percutaneous analgesics and NSAIDs in osteoarthritis (18)
Prof Michael Roberts, University of Queensland, Brisbane, Australia

0935 - 1000
Pharmacology and therapeutics of drugs used to treat OA in veterinary practice (19)
Prof Peter Lees, Royal Veterinary College, London, UK

Cardioprotection from NSAIDs
1000 - 1025
Inhibition of the clinical benefits of aspirin on first MI by nonsteroidal anti-inflammatory drugs (20)
Prof Michael Gaziano, Brigham & Women's Hospital & Harvard Medical School, Boston, MA, USA

 

1025 - 1100 Coffee/Tea

 

1100 - 1125
The cardiovascular effects of concurrent non-selective anti-inflammatory drugs and aspirin (21)
Dr Marie Hudson, McGill University Health Centre, Montreal, Quebec, Canada

1125 - 1150
DISCUSSION: Place of NSAID treatments in patients at risk of cardiovascular disease
All participants

Session 4: OSTEOARTHRITIS - Novel Agents and Procedures
Chair: Prof George Nuki / Prof George Ehrlich

1150 - 1215
Inhibitors of iNOS: potential for symptomatic relief and disease modification in OA (22)
Dr Nigel Boughton-Smith, AstraZeneca, Charnwood, UK

 

1215 - 1315 Lunch

 

Afternoon Session

NO-donating NSAIDs
Chair: Dr Gordon Letts / Dr Nigel Boughton-Smith

1315 - 1350
Nitric Oxide, Inflammation and NSAID-induced gut injury (23)
Prof Brendan Whittle, William Harvey Research Institute, St Bartholomew's & Royal London School of Medicine, London, UK

1350 - 1415
New COX-2 Selective CINODs (24)
Dr Gordon Letts, Nitromed Inc, Boston, MA, USA

1415 - 1440
A new paradigm in pain and inflammation treatment: COX-inhibiting nitric oxide donator (CINOD) (25)
Dr Janet Hoogstraate, AstraZeneca R & D, Södertälje, Sweden

1440 - 1505
The CINOD, AZD 3582, exhibits improved gastrointestinal safety compared with naproxen in healthy volunteers (26)
Dr Bror Jonzon, AstraZeneca R & D, Södertälje, Sweden

 

1505 - 1520 Coffee/Tea

 

Session 5: OSTEOARTHRITIS - Newly-emerging Therapies
Chair: Dr Gordon Letts / Prof Bill Dawson

1520 - 1550
Mechanical signal-transduction pathways in cartilage and chondrocytes in OA - new targets for therapy? (27)
Prof George Nuki, Western General Hospital, University of Edinburgh, Edinburgh, UK

1550 - 1615
Heat shock proteins and their role in chondrocyte protection, an application for autologous transplantation (28)
Dr Michael Seed, William Harvey Research Institute, London, UK

1615 - 1640
Combination therapy for inflammation: synergism of NSAIDs/steroids with some herbal/animal products (29)
Dr Michael Whitehouse, University of Queensland, Brisbane, Australia

1640 - 1705
The effects of opioids and cannabinoids on chondrocytes (30)
Dr Rowena Bunning, Sheffield Hallam University, Sheffield, UK
and
Effects of NSAIDs on cartilage in osteoarthritis (31)
Prof Kim Rainsford, Sheffield Hallam University, Sheffield, UK

Session 6: Novel Aspects of Chronic Diseases
Chair: Prof Nicholas Bellamy / Prof Bill Dawson

1705 - 1730
Arthritic syndromes that defy diagnosis (32)
Prof George Ehrlich, University of Pennsylvania, Philadelphia, PA, USA

1730 - 1755
Immunopathogenesis of autoimmune diseases as a basis for therapeutic targets (33)
Prof Nicola Woodroofe, Sheffield Hallam University, Sheffield, UK

1755 - 1830
Inflammation in the pathogenesis of Alzheimer's disease (34)
Prof David Parkinson, Sheffield Hallam University, Sheffield, UK

1900 Reception

 

1930 - 2200 Conference Dinner

Distinguished Guest and After-Dinner Speaker
Professor George Nuki, Western General Hospital, Edinburgh

 

---

Thursday 24 April

Morning Session

Session 6: Advances in Inflammation Pharmacology
Chair: Dr Brian Callingham / Prof Laurie Prescott

0800 - 0825
Mechanisms of action of paracetamol and related analgesics (35)
Prof Garry Graham, University of New South Wales, Sydney, Australia

0825 - 0850
Recent advances in the kallikrein-kinin system in inflammatory disorders (36)
Prof Jagdish Sharma, University of Kuwait, Safat, Kuwait

0850 - 0915
Novel developments in therapy of inflammatory diseases (37)
Dr Alan Lewis, Celgene Inc., San Diego, CA, USA

0915 - 0940
Insight into the molecular basis of selective COX-2 inhibition (38)
Dr Günter Trummlitz, Boehringer Ingelheim GmbH, Biberach an der Riss, Germany

0940 - 1005
COX-2 selective agents: the bad and not so bad news (39)
Prof Ingvar Bjarnason, Guy's, King's & St Thomas' Medical School, London, UK

1005 - 1030
Cyclo-oxygenase 2 function is essential for bone fracture healing (40)
Prof Patrick O'Connor, UMDNJ - New Jersey Medical School, Newark, NJ, USA

 

1030 - 1100 Coffee/Tea

 

1100 - 1125
Age-related decrease in gastroprotection (41)
Dr Klara Gyires, Semmelweis University, Budapest, Hungary

1125 - 1150
Direct evidence for the exclusion of desensitization of polymodal afferent nerves to capsaicin in the gastro-intestinal tract of healthy human subjects during two weeks treatment with capsaicin (42)
Prof Gyula Mózsik, Pécs University of Medicine. Pécs, Hungary

1150 - 1215
Mechanisms of adverse reactions from NSAIDs and analgesics:
approaches for prevention 43
Prof Kim Rainsford, Sheffield Hallam University, UK

Session 7: Free Oral Communications and Poster Presentations

Posters to be erected for entire period of the conference

1215 - 1345
Poster Discussion: Presenters to give 5-10 minute summary of work on poster followed by 10 minutes discussion

SUMMING-UP and CONCLUSIONS by Chairpersons

* Denotes abstract number

 

---

International Advisory Board

•	Prof Nicholas Bellamy (University of Queensland, Brisbane, Australia)
•	Prof Watson Buchanan (McMaster University, Hamilton, Ontario, Canada)
•	Dr Brian Callingham (University of Cambridge, Cambridge, England, UK)
•	Prof Willlam Dawson (BioNet Ltd, Alton, Hants., England, UK)
•	Prof George Ehrlich (University of Pennsylvania, Philadelphia, PA, USA)
•	Prof Richard Hunt (McMaster University, Hamilton, Ontario, Canada)
•	Prof Walter Kean (McMaster University, Hamilton, Ontario, Canada)
•	Prof George Nuki (Western General Hospital, Edinburgh, Scotland, UK)